Icahn School of Medicine at Mount Sinai
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Icahn School of Medicine at Mount Sinai sits in the top decile of US sponsors by registered trial count (#48 of 15,742 sponsors by registered trial count).
Icahn School of Medicine at Mount Sinai: 708 sponsored US clinical trials, 163 recruiting.
Icahn School of Medicine at Mount Sinai sponsors 708 registered US clinical trials on ClinicalTrials.gov, 163 of them currently recruiting, and 423 completed. 88 of these trials are in Phase 3-4 (later-stage) and 138 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 7 trials.
Top-decile sponsor footprint
Icahn School of Medicine at Mount Sinai ranks in the top decile of sponsors by registered trial count (#48 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
423 of 499 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
708 total, page 5 of 15
Tier Palliative Care For Patients With Advanced Heart Failure or Cancer
NCT07391956
Fareon Open Label Device Clinical Trial
NCT07600320
Harnessing Optimism and Perseverance in the Face of Long COVID-Español
NCT07216040
Understanding and Targeting Self-Regulatory Control in Bulimia Nervosa
NCT07581158
CGM After Discharge From Hospital
NCT07510386
The CHALLENGER Registry
NCT07197840
Gastric Ultrasound in Patients Who Have Undergone Bariatric Surgery
NCT07310875
Hypnosis-Based Machine Learning Biomarker Study
NCT07102810
ExosomeDx in MRI-negative Men With High PSA
NCT06966089
Evaluation of Circadian OS Technology on Melatonin Suppression
NCT07095270
Neurofeedback During Naturalistic Stimuli to Reduce Craving in Heroin Addiction
NCT07344233
Intrarenal Pressure in Suctioning vs. Non-suctioning Sheaths
NCT07619456
Atomoxetine in Melanocortin Obesity Syndrome
NCT06899178
Occlusion Balloon vs. 5FR Ureteral Catheter
NCT06798753
Humanity Neurotech Device Clinical Trial in Adults With Long COVID Cognitive Dysfunction
NCT06739668
Glucose Frequent of A1GDM in Labor
NCT06744621
Optimal Number of Pleural Biopsies During Pleuroscopy
NCT06897878
Investigating the Impact of Duration and Amount of Light on the Circadian System Response - Aim 3
NCT06595030
Auricular Neuromodulation for FESS
NCT06662422
Vestibular Innovation in Pain
NCT06559839
Approach to Dance for Autism
NCT06424366
Frequency of Glucose Monitoring in Labor
NCT06373432
Filtered Eyewear to Prevent Light-induced Melatonin Suppression - Aim 1
NCT06310135
Resilient Together for Dementia
NCT06421545
Erector Spinae Plane Block With Bupivacaine for Medical Thoracoscopy
NCT06313632
Transcutaneous Electrical Nerve Stimulation (TENS) for IUD Insertion Pain
NCT06245655
Impact of Intraoperative Cell Salvage
NCT06240117
A Light Exposure Tracker Designed to Improve Circadian Rhythms - Aim 1
NCT06356337
Physical Therapy vs Remote Exercise for Knee Pain Due to Osteoarthritis (OA)
NCT06167304
Family-Based Interoceptive Exposure for Avoidant Restrictive Food Intake Disorder
NCT06110806
Spesolimab in Pyoderma Gangrenosum
NCT06092216
PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea
NCT06013371
Mitigation of Postoperative Delirium in High-Risk Patients
NCT05777187
Mobile Ostomates Resources for Patients and Caregivers
NCT06157814
Behavioral and Pharmacological Reconsolidation Interference in Misophonia
NCT05928689
Narcotic-Free Percutaneous Nephrolithotomy
NCT05924165
Ritlecitinib in CTCL
NCT05879458
Cardiovascular Precision Medicine & Remote Intervention
NCT05814562
Assessment of Music Experiences in Navigating Depression
NCT06924892
7T MRI for Light Therapy in Patients With Mild Cognitive Impairment and Mild AD
NCT05596994
Postpartum Continuous Glucose Monitoring (CGM) Study
NCT05714761
Methodology Issues in a Tailored Light Treatment for Persons With Dementia - Aim 2
NCT05837819
ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF
NCT05152940
Children's Lifestyle, Diet, and Exercise Intervention - CHILDREN's Project
NCT05630924
GAMBIT Task With PTSD and Healthy Control Participants
NCT05313334
Ruxolitinib in Seborrheic Dermatitis
NCT05787860
The Effect of a Lighting Intervention on Sleep in Parkinson Disease
NCT05771558
VNS for Long-COVID-19
NCT05630040
Vertical Climbing (CLMBR) Exercise for Chronic Low Back Pain
NCT05483608
Duobrii Treatment of Acne Keloidalis Nuchae (AKN)
NCT05608499
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 57 |
| Phase 2 | 81 |
| Phase 3 | 21 |
| Phase 4 | 67 |
Therapeutic Areas
What is open in the Icahn School of Medicine at Mount Sinai pipeline
163 recruiting of 708 indexed (23% open); 423 completed (60%).
Phase mix: 88 late (III/IV) vs 138 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Icahn School of Medicine at Mount Sinai: open-pipeline peers nationwide
Peers matched on 708 registered trials and 23% open enrollment, not the therapeutic-area sidebar.
Icahn School of Medicine at Mount Sinai sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 708 trials (± recruiting share)
- Sanofi · 713 trials · 10% recruiting
- Weill Medical College of Cornell University · 701 trials · 18% recruiting
- University of Miami · 721 trials · 20% recruiting
- The Cleveland Clinic · 688 trials · 14% recruiting
Sponsors near 23% open enrollment (± trial volume)
- Clemson University · 23% recruiting · 13 trials
- Liberating Technologies · 23% recruiting · 13 trials
- Rahul Aggarwal · 23% recruiting · 13 trials
- Sequenom · 23% recruiting · 26 trials
Related
What to do with this Icahn School of Medicine at Mount Sinai page
708 registered trials is a research-attention snapshot, not an endorsement of Icahn School of Medicine at Mount Sinai or any single study.
- 163 of Icahn School of Medicine at Mount Sinai's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition Icahn School of Medicine at Mount Sinai studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Icahn School of Medicine at Mount Sinai pipeline card: 708 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.